TWILIO INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that TWILIO INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $399.02M | Mar 1, 2018 |
| FY2017 | Dec 31, 2016 | $277.34M | Mar 1, 2018 |
| FY2017 | Dec 31, 2015 | $166.92M | Mar 1, 2018 |
| FY2016 | Dec 31, 2014 | $88.85M | Feb 22, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.07B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $4.46B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $4.15B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $3.83B | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $2.84B | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $1.76B | Feb 27, 2023 |
| FY2020 | Jun 30, 2020 | $400.85M | Aug 4, 2020 |
| FY2020 | Mar 31, 2020 | $364.87M | May 7, 2020 |
| FY2021 | Dec 31, 2019 | $1.13B | Feb 22, 2022 |
| FY2020 | Jun 30, 2019 | $275.04M | Aug 4, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.48B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $2.28B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $2.04B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $1.81B | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $1.39B | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $915.66M | Feb 27, 2023 |
| FY2020 | Jun 30, 2020 | $209.13M | Aug 4, 2020 |
| FY2020 | Mar 31, 2020 | $193.54M | May 7, 2020 |
| FY2021 | Dec 31, 2019 | $608.92M | Feb 22, 2022 |
| FY2020 | Jun 30, 2019 | $150.02M | Aug 4, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.83M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($109.40M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($1.02B) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($1.26B) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($949.90M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($490.98M) | Feb 27, 2023 |
| FY2020 | Jun 30, 2020 | ($99.92M) | Aug 4, 2020 |
| FY2020 | Mar 31, 2020 | ($94.79M) | Aug 4, 2020 |
| FY2021 | Dec 31, 2019 | ($307.06M) | Feb 22, 2022 |
| FY2020 | Jun 30, 2019 | ($92.58M) | Aug 4, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $157.80M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($53.71M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($876.54M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($1.21B) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($915.58M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($492.90M) | Feb 27, 2023 |
| FY2020 | Jun 30, 2020 | ($102.64M) | Aug 4, 2020 |
| FY2020 | Mar 31, 2020 | ($92.70M) | May 7, 2020 |
| FY2021 | Dec 31, 2019 | ($369.79M) | Feb 22, 2022 |
| FY2020 | Jun 30, 2019 | ($93.73M) | Aug 4, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.02B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.01B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $942.79M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $1.08B | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $789.22M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $530.55M | Feb 27, 2023 |
| FY2020 | Jun 30, 2020 | $120.70M | Aug 4, 2020 |
| FY2020 | Mar 31, 2020 | $114.34M | May 7, 2020 |
| FY2021 | Dec 31, 2019 | $391.36M | Feb 22, 2022 |
| FY2020 | Jun 30, 2019 | $98.78M | Aug 4, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.00B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $716.24M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $414.75M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($254.37M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($58.19M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $32.65M | Feb 27, 2023 |
| FY2020 | Jun 30, 2020 | $13.91M | Aug 4, 2020 |
| FY2020 | Mar 31, 2020 | $15.54M | May 7, 2020 |
| FY2021 | Dec 31, 2019 | $14.05M | Feb 22, 2022 |
| FY2020 | Jun 30, 2019 | ($13.82M) | Aug 4, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $46.05M | Feb 22, 2022 |
| FY2021 | Dec 31, 2020 | $25.81M | Feb 22, 2022 |
| FY2020 | Jun 30, 2020 | $12.80M | Aug 4, 2020 |
| FY2020 | Mar 31, 2020 | $6.32M | May 7, 2020 |
| FY2021 | Dec 31, 2019 | $45.37M | Feb 22, 2022 |
| FY2020 | Jun 30, 2019 | $7.88M | Aug 4, 2020 |
| FY2020 | Mar 31, 2019 | $2.65M | May 7, 2020 |
| FY2020 | Dec 31, 2018 | $5.11M | Feb 26, 2021 |
| FY2018 | Dec 31, 2017 | $9.25M | Mar 1, 2019 |
| FY2018 | Dec 31, 2016 | $14.17M | Mar 1, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.77B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $9.87B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $11.61B | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $12.56B | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $13.00B | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $9.49B | Feb 22, 2022 |
| FY2020 | Jun 30, 2020 | $5.29B | Aug 4, 2020 |
| FY2020 | Mar 31, 2020 | $5.17B | May 7, 2020 |
| FY2020 | Dec 31, 2019 | $5.15B | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $1.03B | Mar 2, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.95B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.91B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $1.88B | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $2.01B | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $1.97B | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $1.03B | Feb 22, 2022 |
| FY2020 | Jun 30, 2020 | $968.98M | Aug 4, 2020 |
| FY2020 | Mar 31, 2020 | $909.74M | May 7, 2020 |
| FY2020 | Dec 31, 2019 | $871.11M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $590.48M | Mar 2, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.82B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $7.95B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $9.73B | Feb 24, 2026 |
| FY2025 | Dec 31, 2022 | $10.56B | Feb 24, 2026 |
| FY2024 | Dec 31, 2021 | $11.03B | Feb 26, 2025 |
| FY2023 | Dec 31, 2020 | $8.45B | Feb 27, 2024 |
| FY2020 | Jun 30, 2020 | $4.32B | Aug 4, 2020 |
| FY2020 | Mar 31, 2020 | $4.26B | Aug 4, 2020 |
| FY2022 | Dec 31, 2019 | $4.28B | Feb 27, 2023 |
| FY2020 | Jun 30, 2019 | $4.30B | Aug 4, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.29B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $5.24B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $5.24B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $5.28B | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $5.26B | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $4.60B | Feb 27, 2023 |
| FY2020 | Jun 30, 2020 | $2.29B | Aug 4, 2020 |
| FY2020 | Mar 31, 2020 | $2.29B | May 7, 2020 |
| FY2021 | Dec 31, 2019 | $2.30B | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $38.17M | Feb 26, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.34B) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($7.52B) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($5.07B) | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | ($3.38B) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($2.12B) | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | ($1.17B) | Feb 22, 2022 |
| FY2020 | Jun 30, 2020 | ($873.53M) | Aug 4, 2020 |
| FY2020 | Mar 31, 2020 | ($773.60M) | May 7, 2020 |
| FY2020 | Dec 31, 2019 | ($678.81M) | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | ($371.67M) | Mar 2, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $682.34M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $421.30M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $655.93M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $651.75M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $1.48B | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $933.89M | Feb 27, 2023 |
| FY2020 | Jun 30, 2020 | $475.70M | Aug 4, 2020 |
| FY2020 | Mar 31, 2020 | $345.52M | May 7, 2020 |
| FY2021 | Dec 31, 2019 | $253.74M | Feb 22, 2022 |
| FY2019 | Dec 31, 2018 | $487.22M | Mar 2, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $992.29M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $990.59M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $988.95M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $987.38M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $985.91M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $302.07M | Feb 22, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | (5) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | (6) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | (5) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | (3) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | (2) | Feb 22, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | (5) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | (6) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | (5) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | (3) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | (2) | Feb 22, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 152.41M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 152.61M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | 181.95M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | 185.98M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | 180.47M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | 164.05M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | 138.41M | Feb 26, 2021 |
| FY2018 | Dec 31, 2018 | 100.08M | Mar 1, 2019 |
| FY2018 | Dec 31, 2017 | 93.97M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | 87.25M | Mar 1, 2018 |